Back to results
US 2026/0306487 A1Published application
Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
AssigneeGenentech, Inc.
InventorsTamiko KATSUMOTO, Leslie CHINN, Alyssa Mariko MORIMOTO, David James HADDON
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosus using fenebrutinib, an inhibitor of Bruton's tyrosine kinase, or a pharmaceutically acceptable salt thereof.
Claims20
A method of treating a human patient having chronic spontaneous urticaria, wherein the patient is disease symptomatic despite prior H1 antihistamine treatment, the method comprising the administration of fenebrutinib, or a pharmaceutically acceptable salt thereof, at a dose of about 150 mg to about 400 mg daily.
Dependencies are inferred from the claim text.